US37733W2044 - ADR - After market: 35.3599 +0.06 (+0.17%)
GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.
These low-priced equities could deliver enormous returns for risk-tolerant shareholders.
Moderna could follow closely behind Pfizer and GSK in entering the lucrative RSV vaccine market.
Microsoft and Google are slashing jobs. Netflix and Tesla jumped.
After years of lab failures, the companies could crack open a multibillion-dollar market.
Moderna (MRNA) added ~8% in early trading Wednesday as Bank of America welcomed the company's Phase 3 data for mRNA-1345, its respiratory syncytial virus vaccine. Read the full story here.
Moderna is stepping up to Pfizer and GSK, both of which are developing RSV vaccines.
CureVac N.V. (CVAC) extended recent gains on Tuesday after encouraging early-stage data for its mRNA-based vaccines and following the appointment of new CEO. Read the full story here.
CureVac (CVAC) closed ~29% higher on Friday, after posting Phase 1 data for mRNA-based COVID-19 and flu vaccine candidates the company co-develops with GSK (GSK). Read the full story here.
CureVac announced positive results for its mRNA-based Covid-19 and flu vaccine, which may offer tremendous relevance for CVAC stock.
/CNW/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a...
/PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today...
COVID-19 may have lost its daily news headline status, but the disease rages on with 2700 weekly deaths in the U.S. and millions of Americans chronically disabled from long-COVID, 4 million of which are being kept from work. This winter time, a terrible year for RSV as well as a potentially worse flu season could add insult to injury especially when one considers the fact that COVID-19 leaves some people with an impaired immune system similar to what HIV does to cause AIDS. The multiplication of disease could amplify the risks of influenza and RSV to result in more severe cases of these diseases which may result in increased deaths and morbidity. And that isn’t something our country nor the world can afford. There are already reports of Tamiflu generics being in short supply, and it’s just barely the New Year. Fortunately, there are several biotech and pharma companies advancing solutions for RSV, flu, and COVID, including two that may have a solution for all three of these viruses that are currently plaguing the U.S. However, deciding which ones are worth an investment in is not necessarily an easy task.
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now.
A court in Helsinki ordered payment of indemnities to a group of Finnish patients who allegedly got a sleep disorder called narcolepsy as a side effect of GSK's (GSK) flu...
These drug stocks to buy look poised to generate huge profits for investors in 2023 and in subsequent years.
GSK (GSK) said on Wednesday that the U.K.'s Medicines and Healthcare products Regulatory Agency ((MHRA)) authorized the company and Sanofi's (SNY) COVID-19 booster...
Sanofi (SNY) and Pfizer (PFE) have reached an agreement in a Zantac case in California that was set to go to trial.
The tech space is still bursting with opportunities for long-term investors.
ViiV Healthcare has won regulatory support in EU for a new dispersible tablet formulation of its HIV drug Triumeq PD for children. Read the full story here.
Wave Life Sciences (WVE) and GSK (GSK) are collaborating to discover oligonucleotide therapeutics for novel genetic targets.Oligonucleotides are short strands of DNA or RNA which...
GSK (GSK) said 48 week data from a study showed that momelotinib maintained total symptom response ((TSS)), transfusion independence ((TI)) and splenic response in the majority of...
Large-cap pharmaceuticals Pfizer and Johnson & Johnson are outperforming the broader market in the past year, particularly in the past three months.
Shares of France-based biotech Valneva SE (VALN) trended lower in European trading after France's public health body advised against the use of its COVID shot. Read the full story here.
GSK (GSK), Sanofi (SNY) (SNYNF), and Haleon (HLN) rose in European trading on Wednesday as analysts cheered a judgement in Florida related to heartburn drug Zantac. Read full story here.